Literature DB >> 24390738

The transcriptional regulatory network of proneural glioma determines the genetic alterations selected during tumor progression.

Adam M Sonabend1, Mukesh Bansal2,3, Paolo Guarnieri2,3, Liang Lei4, Benjamin Amendolara1, Craig Soderquist4, Richard Leung4, Jonathan Yun1, Benjamin Kennedy1, Julia Sisti1, Samuel Bruce1, Rachel Bruce1, Reena Shakya5, Thomas Ludwig5, Steven Rosenfeld6, Peter A Sims2,7, Jeffrey N Bruce1, Andrea Califano2,3,7,8,9,10, Peter Canoll1,4.   

Abstract

Proneural glioblastoma is defined by an expression pattern resembling that of oligodendrocyte progenitor cells and carries a distinctive set of genetic alterations. Whether there is a functional relationship between the proneural phenotype and the associated genetic alterations is unknown. To evaluate this possible relationship, we performed a longitudinal molecular characterization of tumor progression in a mouse model of proneural glioma. In this setting, the tumors acquired remarkably consistent genetic deletions at late stages of progression, similar to those deleted in human proneural glioblastoma. Further investigations revealed that p53 is a master regulator of the transcriptional network underlying the proneural phenotype. This p53-centric transcriptional network and its associated phenotype were observed at both the early and late stages of progression, and preceded the proneural-specific deletions. Remarkably, deletion of p53 at the time of tumor initiation obviated the acquisition of later deletions, establishing a link between the proneural transcriptional network and the subtype-specific deletions selected during glioma progression. ©2014 AACR

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24390738      PMCID: PMC3981545          DOI: 10.1158/0008-5472.CAN-13-2150

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  44 in total

1.  Heterogeneity of cycling glial progenitors in the adult mammalian cortex and white matter.

Authors:  J M Gensert; J E Goldman
Journal:  J Neurobiol       Date:  2001-08

2.  Loss of heterozygosity at 11p15 and p53 alterations in malignant gliomas.

Authors:  M Schiebe; P Ohneseit; W Hoffmann; R Meyermann; H P Rodemann; M Bamberg
Journal:  J Cancer Res Clin Oncol       Date:  2001-05       Impact factor: 4.553

3.  A platelet factor stimulating human normal glial cells.

Authors:  B Westermark; A Wasteson
Journal:  Exp Cell Res       Date:  1976-03-01       Impact factor: 3.905

4.  Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization.

Authors:  Göran Jönsson; Tara L Naylor; Johan Vallon-Christersson; Johan Staaf; Jia Huang; M Renee Ward; Joel D Greshock; Lena Luts; Håkan Olsson; Nazneen Rahman; Michael Stratton; Markus Ringnér; Ake Borg; Barbara L Weber
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

Review 5.  The cellular origin for malignant glioma and prospects for clinical advancements.

Authors:  Hui Zong; Roel G W Verhaak; Peter Canoll
Journal:  Expert Rev Mol Diagn       Date:  2012-05       Impact factor: 5.225

6.  Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line.

Authors:  Nathalie Auger; Joëlle Thillet; Krystell Wanherdrick; Ahmed Idbaih; Marie-Emmanuelle Legrier; Bernard Dutrillaux; Marc Sanson; Marie-France Poupon
Journal:  Mol Cancer Ther       Date:  2006-09       Impact factor: 6.261

7.  Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain.

Authors:  Lionel M L Chow; Raelene Endersby; Xiaoyan Zhu; Sherri Rankin; Chunxu Qu; Junyuan Zhang; Alberto Broniscer; David W Ellison; Suzanne J Baker
Journal:  Cancer Cell       Date:  2011-03-08       Impact factor: 31.743

8.  A genetic screen identifies TCF3/E2A and TRIAP1 as pathway-specific regulators of the cellular response to p53 activation.

Authors:  Zdenek Andrysik; Jihye Kim; Aik Choon Tan; Joaquín M Espinosa
Journal:  Cell Rep       Date:  2013-05-16       Impact factor: 9.423

9.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

10.  Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma.

Authors:  Kenneth L Pitter; Craig J Galbán; Stefanie Galbán; Omid Saeed Tehrani; Omid Saeed-Tehrani; Fei Li; Nikki Charles; Michelle S Bradbury; Oren J Becher; Thomas L Chenevert; Alnawaz Rehemtulla; Brian D Ross; Eric C Holland; Dolores Hambardzumyan
Journal:  PLoS One       Date:  2011-01-18       Impact factor: 3.240

View more
  29 in total

Review 1.  Biomarkers for glioma immunotherapy: the next generation.

Authors:  Jennifer S Sims; Timothy H Ung; Justin A Neira; Peter Canoll; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2015-02-28       Impact factor: 4.130

2.  Myosin IIA suppresses glioblastoma development in a mechanically sensitive manner.

Authors:  Hannah S Picariello; Rajappa S Kenchappa; Vandana Rai; James F Crish; Athanassios Dovas; Katarzyna Pogoda; Mariah McMahon; Emily S Bell; Unnikrishnan Chandrasekharan; Amanda Luu; Rita West; Jan Lammerding; Peter Canoll; David J Odde; Paul A Janmey; Thomas Egelhoff; Steven S Rosenfeld
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-24       Impact factor: 11.205

3.  Olig2-Dependent Reciprocal Shift in PDGF and EGF Receptor Signaling Regulates Tumor Phenotype and Mitotic Growth in Malignant Glioma.

Authors:  Fanghui Lu; Ying Chen; Chuntao Zhao; Haibo Wang; Danyang He; Lingli Xu; Jincheng Wang; Xuelian He; Yaqi Deng; Ellen E Lu; Xue Liu; Ravinder Verma; Hong Bu; Rachid Drissi; Maryam Fouladi; Anat O Stemmer-Rachamimov; Dennis Burns; Mei Xin; Joshua B Rubin; El Mustapha Bahassi; Peter Canoll; Eric C Holland; Q Richard Lu
Journal:  Cancer Cell       Date:  2016-05-09       Impact factor: 31.743

4.  Convection-enhanced delivery of etoposide is effective against murine proneural glioblastoma.

Authors:  Adam M Sonabend; Arthur S Carminucci; Benjamin Amendolara; Mukesh Bansal; Richard Leung; Liang Lei; Ronald Realubit; Hai Li; Charles Karan; Jonathan Yun; Christopher Showers; Robert Rothcock; Jane O; Andrea Califano; Peter Canoll; Jeffrey N Bruce
Journal:  Neuro Oncol       Date:  2014-03-16       Impact factor: 12.300

Review 5.  Harnessing OLIG2 function in tumorigenicity and plasticity to target malignant gliomas.

Authors:  Jennifer Kosty; Fanghui Lu; Robert Kupp; Shwetal Mehta; Q Richard Lu
Journal:  Cell Cycle       Date:  2017-08-14       Impact factor: 4.534

6.  Ribosome profiling reveals a cell-type-specific translational landscape in brain tumors.

Authors:  Christian Gonzalez; Jennifer S Sims; Nicholas Hornstein; Angeliki Mela; Franklin Garcia; Liang Lei; David A Gass; Benjamin Amendolara; Jeffrey N Bruce; Peter Canoll; Peter A Sims
Journal:  J Neurosci       Date:  2014-08-13       Impact factor: 6.167

7.  MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma.

Authors:  Brian J Gill; David J Pisapia; Hani R Malone; Hannah Goldstein; Liang Lei; Adam Sonabend; Jonathan Yun; Jorge Samanamud; Jennifer S Sims; Matei Banu; Athanassios Dovas; Andrew F Teich; Sameer A Sheth; Guy M McKhann; Michael B Sisti; Jeffrey N Bruce; Peter A Sims; Peter Canoll
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-11       Impact factor: 11.205

8.  Pathway and network analysis of cancer genomes.

Authors:  Pau Creixell; Jüri Reimand; Syed Haider; Guanming Wu; Tatsuhiro Shibata; Miguel Vazquez; Ville Mustonen; Abel Gonzalez-Perez; John Pearson; Chris Sander; Benjamin J Raphael; Debora S Marks; B F Francis Ouellette; Alfonso Valencia; Gary D Bader; Paul C Boutros; Joshua M Stuart; Rune Linding; Nuria Lopez-Bigas; Lincoln D Stein
Journal:  Nat Methods       Date:  2015-07       Impact factor: 28.547

9.  CD8+ T-cell-Mediated Immunoediting Influences Genomic Evolution and Immune Evasion in Murine Gliomas.

Authors:  Joshua R Kane; Junfei Zhao; Takashi Tsujiuchi; Brice Laffleur; Víctor A Arrieta; Aayushi Mahajan; Ganesh Rao; Angeliki Mela; Crismita Dmello; Li Chen; Daniel Y Zhang; Edgar González-Buendia; Catalina Lee-Chang; Ting Xiao; Gerson Rothschild; Uttiya Basu; Craig Horbinski; Maciej S Lesniak; Amy B Heimberger; Raul Rabadan; Peter Canoll; Adam M Sonabend
Journal:  Clin Cancer Res       Date:  2020-05-19       Impact factor: 12.531

10.  Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma.

Authors:  Rebecca S Lescarbeau; Liang Lei; Katrina K Bakken; Peter A Sims; Jann N Sarkaria; Peter Canoll; Forest M White
Journal:  Mol Cancer Ther       Date:  2016-05-17       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.